Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

A highly collaborative investment professional and research analyst with 10+ years of international experience in equity research, treasury operations, and trading positions across multiple asset classes at leading multinational banks Citibank and Morgan Stanley, UHNWI-backed family office and European independent equity research firm. A respectable background in equity capital markets, corporate treasury, investment banking operations, equity research analysis and portfolio management.

Jiangxi Rimag IPO (2522.HK): Global Offering and Valuation Update

Jiangxi Rimag Group Lock-Up Expiry: Cornerstone Investor May Sell Shares After 200%+ Post-IPO Gains

Jiangxi Rimag IPO Preview: Empowering The Future of Medical Imaging Services in China

Equity Capital Markets

Jiangxi Rimag Group / Equity Capital Markets

<ul>
<li>Jiangxi Rimag Group, China's largest medical group with focus on medical imaging services, updated its PHIP and may enter the public market in June.</li>
<li>Terms of an IPO have not yet been set. The expected price range and the size of the offering were not disclosed in the company’s filings. </li>
<li>I’m positive on Jiangxi Rimag Group given the fast-growing TAM: third-party medical imaging center market accounts only for ~1% of the PRC medical imaging service market today.</li>
</ul>


Jiangxi Rimag Group, China's largest medical group with focus on medical imaging services, updated its PHIP and may enter the public market in June.
Terms of an IPO have not yet been set. The expected price range and the size of the offering were not disclosed in the company’s filings. 
I’m positive on Jiangxi Rimag Group given the fast-growing TAM: third-party medical imaging center market accounts only for ~1% of the PRC medical imaging service market today.


Shenzhen Mindray Bio-Medical Electronics (300760 CH)

Shanghai United Imaging Health (688271 CH)

Jiangxi Rimag IPO: FCF Generation and Margin Expansion. Expect ~30 New Imaging Centers By 2026